IBRX - ImmunityBio, Inc. Stock Price and Quote

IBRX [NASD]

Index	-	P/E	-	EPS (ttm)	-1.04	Insider Own	79.16%	Shs Outstand	403.64M	Perf Week	7.00%
Market Cap	588.36M	Forward P/E	-	EPS next Y	-0.68	Insider Trans	0.00%	Shs Float	83.44M	Perf Month	-50.67%
Income	-416.60M	PEG	-	EPS next Q	-0.27	Inst Own	10.30%	Short Float / Ratio	27.38% / 7.88	Perf Quarter	-76.41%
Sales	0.20M	P/S	2941.79	EPS this Y	-16.90%	Inst Trans	16.60%	Short Interest	22.85M	Perf Half Y	-72.42%
Book/sh	-1.11	P/B	-	EPS next Y	-3.00%	ROA	-117.10%	Target Price	9.00	Perf Year	-74.33%
Cash/sh	0.25	P/C	5.49	EPS next 5Y	-1.70%	ROE	102.30%	52W Range	1.21 - 7.80	Perf YTD	-70.03%
Dividend	-	P/FCF	-	EPS past 5Y	-13.40%	ROI	-152.20%	52W High	-80.52%	Beta	1.47
Dividend %	-	Quick Ratio	0.30	Sales past 5Y	39.80%	Gross Margin	-	52W Low	25.57%	ATR	0.24
Employees	725	Current Ratio	0.30	Sales Q/Q	-75.00%	Oper. Margin	-	RSI (14)	23.43	Volatility	15.97% 13.69%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-16.70%	Profit Margin	-	Rel Volume	0.92	Prev Close	1.35
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	2.90M	Price	1.52
Recom	1.50	SMA20	-21.64%	SMA50	-53.57%	SMA200	-65.73%	Volume	230,598	Change	12.55%

Aug-03-22

Initiated

Jefferies

Buy

Feb-16-23 09:00AM	ImmunityBio to Present Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15RFc superagonist N-803 plus BCG at ASCO GU Business Wire -7.71%
Feb-15-23 09:00AM	ImmunityBio Announces Execution of $50 Million Equity Financing with Multiple Institutional Investors Business Wire -6.42%
Jan-19-23 09:00AM	ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration Business Wire
Dec-12-22 08:30AM	ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor Business Wire +10.08%
Nov-17-22 09:00AM	ImmunityBio to Participate in 34th Annual Piper Sandler Healthcare Conference Business Wire
05:21PM	Loading…
Nov-10-22 05:21PM	NEJM Evidence Publishes Results for ImmunityBios QUILT 3.032 Registrational Trial of IL-15 Superagonist N-803 Plus BCG in Patients with Bladder Cancer Business Wire +20.23%
Oct-27-22 08:00AM	ImmunityBio to Participate in the Jefferies London Healthcare Conference Business Wire
Jul-28-22 04:18PM	ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ Business Wire
Jul-26-22 04:17PM	Fauci on needing a second generation of COVID vaccines: 'We have multiple variants of concern ... And it's getting more complicated' Yahoo Finance
Jun-30-22 10:00AM	ImmunityBio may have saved the day in Dunkirk, but it faces the same challenges as Athenex American City Business Journals
Jun-14-22 11:25AM	Health authorities push for a vaccine patent waiver to 'genuinely' prepare for the next pandemic Yahoo Finance
Jun-06-22 09:00AM	ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting Business Wire
May-23-22 08:32AM	ImmunityBio Submits Biologics License Application for N-803 Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ Business Wire
May-16-22 07:29AM	What Percentage Of ImmunityBio, Inc. (NASDAQ:IBRX) Shares Do Insiders Own? Simply Wall St. +11.46%
Apr-28-22 09:00AM	ImmunityBio To Present Data From Multiple Clinical Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Business Wire
09:00AM	Loading…
Apr-25-22 09:00AM	ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer Business Wire
Apr-01-22 04:15PM	ImmunityBio Provides Updated Status of Biologics License Application (BLA) for VesAnktiva Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ Business Wire
Mar-02-22 09:00AM	Memory Cytokine-Enhanced Natural Killer Cells Show Promising Results in Leukemia Patients; Data Support ImmunityBios Scaled m-ceNK Clinical Program Business Wire
Feb-21-22 09:32AM	'The idea that there's not enough human capital in South Africa is outrageous': Dr. Patrick Soon-Shiong Yahoo Finance
Feb-18-22 12:13PM	Biden's renewed cancer moonshot is 'laudable effort': Dr. Patrick Soon-Shiong Yahoo Finance
Feb-15-22 09:00AM	ImmunityBio Completes Acquisition of Athenexs Interest in Dunkirk, New York Advanced Biotech Manufacturing Facility Business Wire +22.26%
09:00AM	Athenex Announces Completion of Sale of Dunkirk Manufacturing Facility GlobeNewswire
Feb-14-22 05:17PM	ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New Magnitude of Benefit in Patients with BCG Unresponsive Bladder Cancer Business Wire
Jan-31-22 07:16PM	ImmunityBio Announces Promising Clinical Study Results for Kick and Kill HIV Cure Strategy to Reduce HIV Viral Load with Anktiva (N-803) Therapy Business Wire +12.57%
Jan-21-22 09:38PM	Liberty One Investment Management, Llc Buys Fastly Inc, Kratos Defense & Security Solutions ... GuruFocus.com
Jan-19-22 07:34AM	Billionaire Soon-Shiong Launches 1 Billion-Dose Vaccine Plant in Cape Town Bloomberg
Jan-18-22 06:00PM	ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Survival Business Wire -7.20%
Jan-13-22 09:00AM	Inside the Athenex-ImmunityBio deal and the California company's employment plans American City Business Journals
Jan-12-22 08:30AM	ImmunityBio Expands Manufacturing Capacity with State-of-the-Art Manufacturing Plant in New York for Global Pandemic Response and Preparedness Business Wire
08:30AM	Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility GlobeNewswire
09:00AM	Loading…
Jan-04-22 09:00AM	ImmunityBio Awarded Seminal Patent on Natural Killer Cells Business Wire -6.91%
Jan-03-22 08:00AM	AMYRIS AND IMMUNITYBIO COMPLETE JOINT VENTURE FOR NEXT GENERATION COVID-19 RNA VACCINE PR Newswire +23.85%
Dec-20-21 09:00AM	ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder Cancer BLA Filing Business Wire
Dec-07-21 06:38AM	What Type Of Shareholders Own The Most Number of ImmunityBio, Inc. (NASDAQ:IBRX) Shares? Simply Wall St. +5.80%
Nov-18-21 09:00AM	ImmunityBio Expands Vaccine Program to Accelerate Use of "Mix-and-Match" Technologies in Developing and Manufacturing Next-Generation COVID-19 Vaccines Business Wire -6.31%
Nov-08-21 05:14PM	Amyris takes bite out of sharks with Covid vaccine joint venture American City Business Journals
08:00AM	Amyris Announces JV Partnership With ImmunityBio For Next Generation COVID-19 RNA Vaccine PR Newswire
Nov-04-21 09:00AM	ImmunityBio to Present at the Jefferies London Healthcare Conference Business Wire
Oct-19-21 09:00AM	ImmunityBio Announces Primary Endpoint Met in a Second Indication in Bladder Cancer Trial with 57% Disease-Free Survival in Patients with BCG Unresponsive Papillary Disease Business Wire
Oct-13-21 09:00AM	ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients90% of Patients Have Exceeded Historical Survival Rates to Date Business Wire
Oct-04-21 08:30AM	National Cancer Institute Selects ImmunityBios N-803 IL-15 Receptor Agonist to Combine with Keytruda in 700-Site Lung-MAP Clinical Trial of a Chemo-Free Therapy Business Wire
Sep-13-21 08:30AM	ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-free in Phase 2/3 Trial Business Wire
Sep-07-21 08:30AM	ImmunityBio Builds Commercial Team with the Appointment of Seasoned Marketing and Reimbursement Executives Business Wire
Sep-01-21 09:00AM	ImmunityBio Announces Oral Presentation of Phase 2/3 Clinical Trial Results of Patients with BCG-Unresponsive Bladder Cancer Carcinoma at the Upcoming American Urological Associations Annual Meeting Business Wire
Aug-16-21 09:00AM	ImmunityBio Appoints Dr. Patrick Soon-Shiong to Global Chief Scientific and Medical Officer; Newly Created Role Will Lead Companys Scientific Strategy and Global Expansion Business Wire
Jul-27-21 09:00AM	ImmunityBios Novel Immunotherapy NANT Cancer Vaccine Currently Being Studied in Multiple Clinical Trials Is Awarded a U.S. Patent Business Wire
Jul-14-21 09:00AM	ImmunityBio Announces Authorization to Proceed with Phase 1/2/3 Randomized Trial in South Africa of Their Dual-Antigen T-Cell Vaccine as a Universal Boost in Previously Vaccinated Participants Against COVID-19 Business Wire
Jun-28-21 09:00AM	ImmunityBio and NantOmics Announce Clinical Validation of a Proprietary Method to Identify Unique Targets for Immunotherapy in Individual Breast Cancer Patients Business Wire +5.33%
Jun-23-21 04:05PM	Motus GI Appoints Experienced Financial Biotech Executive, Sonja Nelson, to its Board of Directors and as Chair of Audit Committee GlobeNewswire
Jun-15-21 07:00AM	FDA Authorizes ImmunityBio Study of Anktiva and PD-L1 t-haNK to Increase Effectiveness of Trodelvy in Triple-Negative Breast Cancer Business Wire
Jun-10-21 09:00AM	ImmunityBio Announces HIV Clinical Pipeline with Opening of a Phase 1 HIV Cure Study in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients Business Wire
04:35AM	Do Insiders Own Lots Of Shares In ImmunityBio, Inc. (NASDAQ:IBRX)? Simply Wall St.
May-25-21 09:00AM	ImmunityBio Expands Trials of T-Cell-Based COVID-19 Vaccine Candidate as a Universal Boost in Vaccinated Subjects and Receives Approval to Test Intranasal Spray in South Africa Business Wire
May-24-21 09:00AM	ImmunityBio to Present at the Jefferies 2021 Virtual Healthcare Conference Business Wire
May-20-21 09:00AM	ImmunityBio to Present Preliminary Phase 2 Data of 68% Durable Disease Control with Anktiva Plus Checkpoint Inhibitor in First 140 Patients Enrolled with Lung Cancer and Multiple Tumor Types Who Failed Prior Checkpoint Therapy at ASCO 2021 Business Wire +6.70%
May-17-21 09:00AM	FDA Authorizes ImmunityBio to Conduct a Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell (m-ceNK) Platform in Solid Tumors Business Wire +9.65%
May-04-21 09:00AM	ImmunityBio Announces 78 Percent Complete Response Following Chemotherapy-Free Combination of IL-15 Superagonist Anktiva with Rituxan in Relapsed Non-Hodgkin Lymphoma Patients Business Wire -8.35%
Apr-29-21 09:00AM	ImmunityBio Announces Launch of Phase 2 Trial of IL-15 Superagonist Anktiva With Antiretroviral Therapy to Inhibit HIV Reservoirs Business Wire -7.24%
Apr-22-21 09:00AM	ImmunityBio Announces 100th Patient Dosed with Proprietary Natural Killer Cells; NK Trials Cover Multiple Indications Business Wire
Apr-08-21 09:00AM	ImmunityBio Announces Single Prime hAd5 COVID-19 Vaccination Induces a 10-Fold Increase in T Cell Response Equivalent to T Cell Responses from Patients Previously Infected with SARS-CoV-2 Business Wire
Apr-01-21 09:00AM	ImmunityBio Appoints Dr. Linda Maxwell and CEO Richard Adcock to Board of Directors Business Wire -5.64%
Mar-29-21 09:00AM	ImmunityBio Announces 12-Month Overall Survival Probability of 83% in NCI-Led Phase 1 Study of Multi-Targeted hAd5 Immunotherapy Vaccine in Patients with Advanced Metastatic Prostate Cancer Business Wire -7.92%
Mar-26-21 03:04PM	'Unless we vaccinate the entire planet, we won't get rid of this pandemic:' Vaccine developer Yahoo Finance -13.31%
03:00PM	Yahoo Finance Presents: Dr. Patrick Soon-Shiong Yahoo Finance Video
Mar-22-21 09:00AM	ImmunityBio Announces NIH-Led Research Affirming that PD-L1 T-haNK Therapy Overcomes T-Cell Escape in Multiple Types of Resistant Tumors Business Wire +7.23%
Mar-15-21 09:00AM	ImmunityBio Announces Positive Interim Phase I Safety Data of hAd5 T-Cell COVID-19 Vaccine Candidate in Oral and Sublingual Formulations Business Wire
Mar-11-21 09:00AM	ImmunityBio Announces Novel ACE2 Decoy COVID-19 Therapeutic that Shows High Binding to SARS-CoV-2 Variants and Neutralizes Live Viruses Business Wire -12.07%
Mar-10-21 09:00AM	ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company Business Wire +19.11%

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Adcock Richard	CEO & President	Feb 05	Option Exercise	0.00	83,333	0	227,774	Feb 07 06:23 PM
Adcock Richard	CEO & President	Dec 31	Option Exercise	0.00	8,620	0	148,714	Jan 04 09:48 PM
Sachs David C.	Chief Financial Officer	Dec 31	Option Exercise	0.00	7,598	0	51,298	Jan 04 09:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience